Patient sentiments on tobacco industry ownership of respiratory therapies

The COPD Foundation partnered with GAAPP and Lung Foundation Australia to survey individuals with chronic lung diseases to assess Patient sentiments on tobacco industry ownership of respiratory therapies. After acquiring Vectura, a manufacturer of several inhaled therapies for lung diseases, by Philip Morris International, our organizations wanted to take the opportunity to understand the patient perspective on the relationship between tobacco companies and respiratory medication manufacturers.

We found that 70% of respondents from regions around the world were unhappy with this development. In addition, free text feedback received was overwhelmingly negative in nature at 78%. Survey results, as well as anonymous feedback provided, have been published in the official journal of the British Thoracic Society, Thorax.

We would like to thank our partnering member organizations, APEPOC and Latin Health Leaders, for their active contribution!

Infographics

Summary Posters

Participant Organizations